Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $0.39, for a total transaction of $50,220.30. Following the completion of the transaction, the insider directly owned 341,353 shares in the company, valued at $133,127.67. This trade represents a 27.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total transaction of $55,361.25.
- On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $68,176.40.
- On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total value of $99,751.14.
- On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
- On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
- On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $64,736.64.
- On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
- On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.
Werewolf Therapeutics Stock Down 7.4%
NASDAQ HOWL traded down $0.03 during trading on Tuesday, hitting $0.36. 580,233 shares of the stock traded hands, compared to its average volume of 468,701. The company has a market capitalization of $17.50 million, a P/E ratio of -0.29 and a beta of 0.29. The firm has a 50-day simple moving average of $0.65 and a 200-day simple moving average of $0.71. Werewolf Therapeutics, Inc. has a 12-month low of $0.36 and a 12-month high of $2.38.
Analysts Set New Price Targets
Several equities analysts have commented on HOWL shares. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.75.
View Our Latest Stock Report on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
Several institutional investors have recently made changes to their positions in HOWL. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $409,000. Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the 3rd quarter worth about $304,000. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $113,000. Institutional investors own 64.84% of the company’s stock.
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
- Five stocks we like better than Werewolf Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
